In Vivo Preclinical Efficacy & Safety of CAR-T, -NK, and -Myeloid Based Therapies

April 14, 2022

Technical Information Services Manager, Brian Soper, Ph.D., explores recent advances in CAR mediated strategies for human immuno-oncology. Recorded on 4-7-22

In Vivo Preclinical Efficacy & Safety of CAR-T, -NK, and -Myeloid Based Therapies

What Do Experimental Mice Really Cost?

Comparing Immune-Humanized Mouse Platforms for Preclinical Applications

Using Cre-lox Technology in Mouse Modeling

Designing Reproducible Preclinical Research Studies

Comparing Immunodeficient Models for Cancer, Immunity, and Transplant Research

The Consequences of Sex Bias in Preclinical Research

Translatable Efficacy & Safety Testing of mAb, Bispecific, & CAR T Therapies

Key Considerations to Optimize Preclinical Aging Studies

De-Risk Therapeutic Antibody Drug Development Using Humanized FcRn Platforms (Oct. 24, 2023)

New Immune-humanized Models Support More Diverse Human Immune Cell Lineages

Rapid In Vivo Evaluation of Immuno-Modulatory Therapies Using Hu-PBMC NSG™ Mice

Comparing Mouse Models for Obesity and Diabetes Research

The Many Faces of C57BL/6 Mice: Research Impact of B6 Substrain Differences

Essential Tips for Choosing and Using Mouse Models in Research

In Vivo Platforms for Autoimmune Pharmacology: MS-EAE Capabilities

Support the 3 R’s with Effective Mouse Colony Management Practices

Preclinical Assessment of Investigational Gene Therapy Products for Neuroscience

In Vivo Drug Discovery Platforms for Amyotrophic Lateral Sclerosis

Onco-Hu® Mouse Models

Mouse Models of Coronavirus Infection